FeesSafety
Pluang+

Hagerty reports 18% premium growth and record 402K new members in 2026, raising profit outlook.

Company Fundamentals
03 Nov 2026, 13:55 WIB
PRNewsWire
View Source
Bullish
Hagerty reports 18% premium growth and record 402K new members in 2026, raising profit outlook.

Hagerty, Inc. announced strong 2026 results with an 18% increase in written premium to $1.1 billion and a record addition of 402,000 new members, growing policies in force by 18% to 1.9 million. Earned premium rose 42% to $757 million, supported by a new Markel Fronting Arrangement increasing Hagerty Re's quota share to 100%. Despite $189 million in transitional costs, net income reached $32 million and adjusted EBITDA grew 43% to $257 million. The company raised its full-year profit outlook, expecting net income between $48 million and $60 million and adjusted EBITDA of $305 million to $315 million, reflecting confidence in continued growth and operational efficiency.

Hagerty reports strong 2026 growth with an 18% rise in written premium to $1.1 billion and record new members. For readers following Financials, here is Pluang's market snapshot as of Nov 03, 2026 17:51 WIB: out of 142 US Financials stocks, 72 rose and 59 fell. Marathon Digital Holdings Inc (MARA) rose 1.40% to USD 6.52 with 93% buy orders, CleanSpark Inc (CLSK) rose 1.40% to USD 7.25 with 100% buy orders, and ICICI Bank Limited (IBN) rose 1.40% to USD 30.48 with a typical hold time of 13 days.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
2 hours ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
2 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
2 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
3 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App